| The ryanodine receptor in cardiac physiology and disease. | |
| | |
MedLine Citation:
|
PMID: 20933197 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
According to the American Heart Association it is estimated that the United States will spend close to $39 billion in 2010 to treat over five million Americans suffering from heart failure. Patients with heart failure suffer from dyspnea and decreased exercised tolerance and are at increased risk for fatal ventricular arrhythmias. Food and Drug Administration -approved pharmacologic therapies for heart failure include diuretics, inhibitors of the renin-angiotensin system, and β-adrenergic receptor antagonists. Over the past 20 years advances in the field of ryanodine receptor (RyR2)/calcium release channel research have greatly advanced our understanding of cardiac physiology and the pathogenesis of heart failure and arrhythmias. Here we review the key observations, controversies, and discoveries that have led to the development of novel compounds targeting the RyR2/calcium release channel for treating heart failure and for preventing lethal arrhythmias. |
| | |
Authors:
|
Alexander Kushnir; Andrew R Marks |
Related Documents
:
|
12556677 - Hyperthyroidism: a "curable" cause of congestive heart failure--three case reports and ... 18158477 - Systolic heart failure: chronic and acute syndromes. 19372677 - Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment o... 15182777 - Clinical trials update and cumulative meta-analyses from the american college of cardio... 7797747 - Dispersion of qt interval in patients with and without susceptibility to ventricular ta... 8027957 - Cognitive-behavioural interventions in cardiac rehabilitation. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Advances in pharmacology (San Diego, Calif.) Volume: 59 ISSN: 1557-8925 ISO Abbreviation: Adv. Pharmacol. Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-10-11 Completed Date: 2010-11-04 Revised Date: 2011-07-20 |
Medline Journal Info:
|
Nlm Unique ID: 9015397 Medline TA: Adv Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 1-30 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Physiology and Cellular Biophysics, Clyde and Helen Wu Center for Molecular Cardiology, College of Physicians and Surgeons of Columbia University, New York, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Atrial Fibrillation / metabolism*, physiopathology, therapy Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism Cardiovascular Agents / chemistry, metabolism, therapeutic use Cyclic AMP-Dependent Protein Kinases / metabolism Drug Design Heart Conduction System* / physiology, physiopathology Heart Failure / metabolism*, physiopathology, therapy Humans Infant, Newborn Myocardial Contraction* / physiology Phosphorylation Receptors, Adrenergic, beta / metabolism, physiology Ryanodine Receptor Calcium Release Channel / chemistry, drug effects, physiology* Sudden Infant Death / genetics, prevention & control Tachycardia, Ventricular / metabolism*, physiopathology, therapy Tacrolimus Binding Proteins / metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
HL056180/HL/NHLBI NIH HHS; HL061503/HL/NHLBI NIH HHS; P01 HL067849-10/HL/NHLBI NIH HHS; R01 HL056180-15/HL/NHLBI NIH HHS; R01 HL061503-13/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Cardiovascular Agents; 0/Receptors, Adrenergic, beta; 0/Ryanodine Receptor Calcium Release Channel; EC 2.7.11.11/Cyclic AMP-Dependent Protein Kinases; EC 2.7.11.17/Calcium-Calmodulin-Dependent Protein Kinase Type 2; EC 5.2.1.-/Tacrolimus Binding Proteins |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Foreword.
Next Document: Neuregulin-1/ErbB Signaling and Chronic Heart Failure.